Lineage Cell Therapeutics Inc Corporate Analyst Meeting Transcript
Good afternoon, everyone. My name is Jason McCarthy. I am the Head of Biotechnology Equity Research with Maxim Group. And it is with great pleasure to welcome you to today's virtual event, featuring Lineage Cell Therapeutics and an in-depth discussion on the company's allogeneic cell therapy program, OPC1, for treating spinal cord injury.
As a research analyst, as many of my colleagues in the business would tell you, there are any number of therapeutic categories to cover, each with exciting companies and science and medicine that could be and often is transformative. And you could look at oncology, inflammatory disease, gene therapy, NASH. And what about Alzheimer's disease? It's been a pretty hot-button topic just in the last couple of weeks alone.
And these are just a handful of spaces, and all are different. But what links them is that each has had its areas of tremendous success. And with it sometimes comes parabolic-like rises in valuations. So my question is what about cell therapy?
Sure, we can always
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
